Oura Ring Gen 4 sensor data — not clinical measurementsN=1 case study — not validated for clinical decisionsHEV diagnosed Mar 18; interpret findings cautiously in this Day 8 post-ruxolitinib window

Full Biometric Analysis

Wearable-derived biometric summary for the current observation window
Generated 2026-03-27 07:09
RMSSD
Low
10.1ms
Normal: 36-72 ms
Sleep HR
Critical
84.9bpm
Elevated (>80 bpm)
HRV Balance
Low
36/100
Oura readiness contributor
Readiness
Normal
66/100
30-day average
Sleep Score
Low
65/100
19/73 days <60
Daily Steps
Low
2318
43 days <2000
Vascular Age
Info
41yr
Oura estimate across 60 days
SpO2
Normal
96.1%
Lowest: 94.4%

HRV Deep Dive

RMSSD Comparison

Heart Rate

Sleep

Readiness & Recovery

Resilience & Vascular Age

SpO2 & Stress

Activity

Clinical Summary

This summary describes the wearable signals observed in the current data window. It does not assert specific clinical history or diagnosis. Mean RMSSD is 10.1 ms, 79% below the reference median (49 ms).
RMSSD (HRV) 79% below median
10.1 ms
080 ms
Normal: 36-72 ms (P25-P75)
Sleep HR Elevated
85 bpm
40110 bpm
Normal sleep HR: 50-65 bpm
HRV Balance Critically low
36 /100
0100
Normal: 50-80 (Oura readiness component)
Daily Steps 2,318 avg
2,318 steps
010,000
Normal: 5,000-8,000 steps/day
Sleep Moderate
Score 65/100
Duration 6.0 hrs
Poor days 19/73
Sleep HRV 9 ms
Physical Capacity Severe
Activity score 56/100
Days <2k steps 43
Resilience All limited
SpO2 Low Normal
Average 96.1%
Lowest 94.4%
BOS risk Borderline
Vascular Age Estimate Estimate
Mean estimate 41 yr
Observed range 36-47 yr
Available days 60
5,986
RMSSD samples
over 74 days
79%
below reference
median
41 yr
mean vascular age
estimate
Wearable-derived snapshot for this observation window: RMSSD averages 10.1 ms, sleep heart rate is elevated, activity averages 2,318 steps/day, and the Oura vascular age estimate averages 41 yr. These are descriptive wearable outputs only, not confirmed diagnoses or verified medical history.
References (4)
  1. Kleiger RE et al. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987;59:256-62
  2. Bigger JT et al. Frequency domain measures of heart period variability and mortality after myocardial infarction. Circulation 1992;85:164-71
  3. Shaffer F, Ginsberg JP. An Overview of HRV Metrics and Norms. Front Public Health 2017;5:258
  4. Nunan D et al. Normal values for short-term HRV. Pacing Clin Electrophysiol 2010;33:1407-17
All metrics derived from Oura Ring Gen 4 consumer wearable data. Not clinical-grade measurements.
Single-patient case study (N=1). Not validated for clinical decision-making. Not a medical device.
Data: January 08 – March 23, 2026 · Post-intervention: 8 days (ruxolitinib, March 16)
Open source under MIT License · © 2026 The Educational Equality Institute · GitHub
Updated daily at 06:15 CET · Last generated: 2026-03-27 07:09
This project is not affiliated with, endorsed by, or sponsored by Oura Health Oy. Oura® is a registered trademark of Oura Health Oy.